Literature DB >> 9479539

Little effect of tissue plasminogen activator in subretinal surgery for acute hemorrhage in age-related macular degeneration.

L Hesse1, D Meitinger, J Schmidt.   

Abstract

We studied the effect of intraoperative fibrinolysis prior to surgical evacuation of subretinal hemorrhage, which has been recommended as a valuable adjunct in the surgical treatment of submacular hemorrhage. We analyzed retrospectively the records of eight patients who underwent pars plana vitrectomy combined with subretinal injection of tissue plasminogen activator (TPA). The duration of symptoms ranged from 2 h to 14 days (median 1.5 days). During vitrectomy, TPA (6-75 micrograms) was injected subretinally through a retinotomy. After 20 min the liquified blood was surgically drained. The residual clot had to be extracted mechanically through an enlarged retinotomy site. In all patients, fibrinolysis was incomplete and an additional mechanical clot extraction was necessary. The postoperative visual acuity improved slightly in four patients, stabilized at the preoperative level in three patients, and worsened in one patient. During follow-up, one patient suffered from retinal detachment. In four patients a cataract developed. In all eyes, large defects of the retinal pigment epithelium resulted. In contrast to other authors, we did not find an acceptable liquefaction of the subretinal clot that would have facilitated surgical extraction of the hemorrhage. Therefore, a therapeutic benefit from the injection of TPA before removal of a subretinal hemorrhage was not distinct.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9479539

Source DB:  PubMed          Journal:  Ger J Ophthalmol        ISSN: 0941-2921


  4 in total

1.  The end of submacular surgery for age-related macular degeneration? A meta-analysis.

Authors:  Christiane I Falkner; Harald Leitich; Florian Frommlet; Peter Bauer; Susanne Binder
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-05-04       Impact factor: 3.117

2.  [Intravitreal injection. Drugs to treat subretinal hemorrhage].

Authors:  L Hesse
Journal:  Ophthalmologe       Date:  2012-07       Impact factor: 1.059

3.  [Massive subretinal hemorrhages. A challenge for vitreous body surgeons].

Authors:  J C Schmidt; C H Meyer; S Hörle
Journal:  Ophthalmologe       Date:  2004-06       Impact factor: 1.059

4.  Intravitreal Expansile Gas and Bevacizumab Injection for Submacular Hemorrhage Due to Neovascular Age-related Macular Degeneration.

Authors:  Ramin Nourinia; Mohammad Hossein Jabbarpour Bonyadi; Hamid Ahmadieh
Journal:  J Ophthalmic Vis Res       Date:  2010-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.